Recent Finacing
Recent Raise
OverT Bio develops engineered immune-cell therapies for solid tumors using high-throughput pooled functional screening, single-cell multiomics, and synthetic genomics platforms (OverTarget, OverTCR) to identify and program durable anti-tumor receptors.
